Recent studies have focused on the intersection of glucagon-like peptide-1|GIP|glucagon receptor agonist therapies and dopaminergic neurotransmission. While GIP activators are widely employed for treating type 2 https://elodiemvgu668800.collectblogs.com/85659280/novel-gcgr-agonists-and-da-modulation-a-comparative-assessment